Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

Anticancer vaccination is a promising approach to increase the efficacy of cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) checkpoint blockade therapies. However, the landmark FDA registration trial for anti–CTLA-4 therapy (ipilimumab) revealed a complete l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Hailemichael, Yared, Woods, Amber, Fu, Tihui, He, Qiuming, Nielsen, Michael C., Hasan, Farah, Roszik, Jason, Xiao, Zhilan, Vianden, Christina, Khong, Hiep, Singh, Manisha, Sharma, Meenu, Faak, Faisal, Moore, Derek, Dai, Zhimin, Anthony, Scott M., Schluns, Kimberly S., Sharma, Padmanee, Engelhard, Victor H., Overwijk, Willem W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873868/
https://ncbi.nlm.nih.gov/pubmed/29480817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI93303
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados